ID

37603

Beskrivning

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies; ODM derived from: https://clinicaltrials.gov/show/NCT02090543

Länk

https://clinicaltrials.gov/show/NCT02090543

Nyckelord

  1. 2019-08-10 2019-08-10 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

10 augusti 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Atrial Fibrillation NCT02090543

Eligibility Atrial Fibrillation NCT02090543

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
a.general criteria (group 1and group2):
Beskrivning

Criteria General

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C0205246
diagnosed non-valvular af
Beskrivning

Atrial Fibrillation

Datatyp

boolean

Alias
UMLS CUI [1]
C0004238
older than 18 years
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
general capability and willingness to perform a structured patient interview in german
Beskrivning

Patient interview German language

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0683518
UMLS CUI [1,2]
C0017477
no participation in any other clinical or observational study over the last 3 month
Beskrivning

Participation Absent Clinical Trial Other | Participation Absent Observational Study Other

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0679823
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0008976
UMLS CUI [1,4]
C0205394
UMLS CUI [2,1]
C0679823
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C1518527
UMLS CUI [2,4]
C0205394
additional criteria for group1 (vka-experienced):
Beskrivning

Criteria Additional | Group Number

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0441833
UMLS CUI [2,2]
C0237753
active vka-therapy for at least 3 month without significant interruptions
Beskrivning

Vitamin K antagonists

Datatyp

boolean

Alias
UMLS CUI [1]
C3653316
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
Beskrivning

Interruption perioperative | Vitamin K antagonists To be stopped

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1512900
UMLS CUI [1,2]
C1518988
UMLS CUI [2,1]
C3653316
UMLS CUI [2,2]
C1272691
additional criteria for group2 (rivaroxaban-experienced patients):
Beskrivning

Criteria Additional | Group Number

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1524062
UMLS CUI [2,1]
C0441833
UMLS CUI [2,2]
C0237753
active rivaroxaban-therapy for at least 3 month without significant interruptions
Beskrivning

rivaroxaban

Datatyp

boolean

Alias
UMLS CUI [1]
C1739768
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
Beskrivning

Interruption perioperative | Vitamin K antagonists To be stopped

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1512900
UMLS CUI [1,2]
C1518988
UMLS CUI [2,1]
C3653316
UMLS CUI [2,2]
C1272691
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
participation in any other clinical or observational study over the last 3 month
Beskrivning

Study Subject Participation Status | Clinical Trial | Observational Study

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0008976
UMLS CUI [3]
C1518527

Similar models

Eligibility Atrial Fibrillation NCT02090543

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Criteria General
Item
a.general criteria (group 1and group2):
boolean
C0243161 (UMLS CUI [1,1])
C0205246 (UMLS CUI [1,2])
Atrial Fibrillation
Item
diagnosed non-valvular af
boolean
C0004238 (UMLS CUI [1])
Age
Item
older than 18 years
boolean
C0001779 (UMLS CUI [1])
Patient interview German language
Item
general capability and willingness to perform a structured patient interview in german
boolean
C0683518 (UMLS CUI [1,1])
C0017477 (UMLS CUI [1,2])
Participation Absent Clinical Trial Other | Participation Absent Observational Study Other
Item
no participation in any other clinical or observational study over the last 3 month
boolean
C0679823 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C0679823 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1518527 (UMLS CUI [2,3])
C0205394 (UMLS CUI [2,4])
Criteria Additional | Group Number
Item
additional criteria for group1 (vka-experienced):
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0441833 (UMLS CUI [2,1])
C0237753 (UMLS CUI [2,2])
Vitamin K antagonists
Item
active vka-therapy for at least 3 month without significant interruptions
boolean
C3653316 (UMLS CUI [1])
Interruption perioperative | Vitamin K antagonists To be stopped
Item
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
boolean
C1512900 (UMLS CUI [1,1])
C1518988 (UMLS CUI [1,2])
C3653316 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Criteria Additional | Group Number
Item
additional criteria for group2 (rivaroxaban-experienced patients):
boolean
C0243161 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0441833 (UMLS CUI [2,1])
C0237753 (UMLS CUI [2,2])
rivaroxaban
Item
active rivaroxaban-therapy for at least 3 month without significant interruptions
boolean
C1739768 (UMLS CUI [1])
Interruption perioperative | Vitamin K antagonists To be stopped
Item
in case of perioperative interruption vka treatment should not have been hold for more than two weeks.
boolean
C1512900 (UMLS CUI [1,1])
C1518988 (UMLS CUI [1,2])
C3653316 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | Clinical Trial | Observational Study
Item
participation in any other clinical or observational study over the last 3 month
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])
C1518527 (UMLS CUI [3])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial